Kainos Medicine, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kainos Medicine, Inc.
Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate
In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.
Kainos Progresses Parkinson’s Drug US Trials Amid Deal Prospects
Following ABL Bio’s sizable Parkinson’s disease drug deal with Sanofi early this year, Korean bioventure Kainos Medicine is under the spotlight as its novel PD drug candidate enters Phase II in the US.
Asia Deal Watch: Emmaus, Kainos Pursue R&D In Cancers With Limited Therapy Options
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
Korean Pharma Accelerates Coronavirus-Related R&D, Calls For More Support
As South Korean companies jump into the development of vaccines and drugs for the coronavirus, they also call for stronger government support and increased collaboration between the state and private sectors.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.